Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.

Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer S

Open source

DOI: 10.1038/s41591-023-02734-5
Published: 2024 Feb
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-023-02734-5,
  title = {Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.},
  author = {Heinrich MC and Jones RL and George S and Gelderblom H and Schöffski P and von Mehren M and Zalcberg JR and Kang YK and Razak AA and Trent J and Attia S and Le Cesne A and Siontis BL and Goldstein D and Boye K and Sanchez C and Steeghs N and Rutkowski P and Druta M and Serrano C and Somaiah N and Chi P and Reichmann W and Sprott K and Achour H and Sherman ML and Ruiz-Soto R and Blay JY and Bauer S},
  year = {2024},
  journal = {Nature medicine},
  doi = {10.1038/s41591-023-02734-5},
  url = {https://doi.org/10.1038/s41591-023-02734-5}
}

RIS

TY  - JOUR
TI  - Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
AU  - Heinrich MC
AU  - Jones RL
AU  - George S
AU  - Gelderblom H
AU  - Schöffski P
AU  - von Mehren M
AU  - Zalcberg JR
AU  - Kang YK
AU  - Razak AA
AU  - Trent J
AU  - Attia S
AU  - Le Cesne A
AU  - Siontis BL
AU  - Goldstein D
AU  - Boye K
AU  - Sanchez C
AU  - Steeghs N
AU  - Rutkowski P
AU  - Druta M
AU  - Serrano C
AU  - Somaiah N
AU  - Chi P
AU  - Reichmann W
AU  - Sprott K
AU  - Achour H
AU  - Sherman ML
AU  - Ruiz-Soto R
AU  - Blay JY
AU  - Bauer S
PY  - 2024
JO  - Nature medicine
DO  - 10.1038/s41591-023-02734-5
UR  - https://doi.org/10.1038/s41591-023-02734-5
ER  -

APA

MC, H., RL, J., S, G., H, G., P, S., M, V. M., JR, Z., YK, K., AA, R., J, T., S, A., A, L. C., BL, S., D, G., K, B., C, S., N, S., P, R., M, D., C, S., N, S., P, C., W, R., K, S., H, A., ML, S., R, R., JY, B., & S, B. (2024). Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.. Nature medicine. https://doi.org/10.1038/s41591-023-02734-5

Source records

pubmed · retrieved 2026-09-27T00:42:34.803Z
europe-pmc · retrieved 2026-09-27T00:42:34.801Z